A detailed history of Black Rock Inc. transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 798,137 shares of CLSD stock, worth $822,081. This represents 0.0% of its overall portfolio holdings.

Number of Shares
798,137
Previous 758,226 5.26%
Holding current value
$822,081
Previous $1.16 Million 10.6%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.08 - $1.58 $43,103 - $63,059
39,911 Added 5.26%
798,137 $1.04 Million
Q1 2024

May 10, 2024

SELL
$1.2 - $2.02 $1,820 - $3,064
-1,517 Reduced 0.2%
758,226 $1.16 Million
Q4 2023

Feb 13, 2024

SELL
$0.68 - $1.18 $2,372 - $4,117
-3,489 Reduced 0.46%
759,743 $888,000
Q3 2023

Nov 13, 2023

SELL
$0.82 - $1.27 $41,063 - $63,599
-50,078 Reduced 6.16%
763,232 $664,000
Q2 2023

Aug 11, 2023

BUY
$0.97 - $1.48 $14,345 - $21,887
14,789 Added 1.85%
813,310 $910,000
Q1 2023

May 12, 2023

SELL
$0.93 - $1.66 $632 - $1,128
-680 Reduced 0.09%
798,521 $830,000
Q4 2022

Feb 13, 2023

SELL
$1.0 - $1.5 $390,748 - $586,122
-390,748 Reduced 32.84%
799,201 $895,000
Q3 2022

Nov 14, 2022

SELL
$1.08 - $1.83 $24,887 - $42,170
-23,044 Reduced 1.9%
1,189,949 $1.35 Million
Q2 2022

Aug 12, 2022

SELL
$1.3 - $2.49 $8,026 - $15,373
-6,174 Reduced 0.51%
1,212,993 $1.78 Million
Q1 2022

May 12, 2022

SELL
$1.35 - $2.88 $299 - $639
-222 Reduced 0.02%
1,219,167 $2.79 Million
Q4 2021

Feb 10, 2022

BUY
$2.72 - $5.72 $1.13 Million - $2.37 Million
415,037 Added 51.6%
1,219,389 $3.35 Million
Q3 2021

Nov 09, 2021

BUY
$4.83 - $7.2 $158,395 - $236,116
32,794 Added 4.25%
804,352 $4.83 Million
Q2 2021

Aug 11, 2021

BUY
$2.32 - $5.38 $1.79 Million - $4.15 Million
771,558 New
771,558 $3.76 Million

Others Institutions Holding CLSD

About Clearside Biomedical, Inc.


  • Ticker CLSD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,190,700
  • Market Cap $62M
  • Description
  • Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...
More about CLSD
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.